Navigation Links
Watson's GELNIQUE(TM) (oxybutynin chloride) Gel 10% Approved by FDA for the Treatment of Overactive Bladder
Date:1/27/2009

ression. The disease affects both men and women however, women experience more severe symptoms earlier in life.

About Watson Pharmaceuticals, Inc.

Watson Pharmaceuticals, Inc. is a global leader in the development and distribution of pharmaceuticals with a broad portfolio of generic products and a specialized portfolio of branded pharmaceuticals focused on Urology, Gynecology and Nephrology (Medical).

In the U.S., the Watson portfolio includes RAPAFLO, Oxytrol(R); Ferrlecit(R), INFeD(R), TRELSTAR(R) LA; and TRELSTAR(R) Depot. In addition, Watson markets the following brands under co-promotion agreements: AndroGel(R), with Solvay Pharmaceuticals, Inc.; Proquin(R) XR, with Depomed, Inc.; Tri-Luma(R) Cream, with Galderma Laboratories; and Femring(R), with Warner Chilcott Limited. The Watson pipeline portfolio includes a number of products, including a six-month formulation of TRELSTAR(R), for the treatment of advanced prostate cancer which is currently under review by the FDA; URACYST(R), under development for cystitis; and a novel new oral contraceptive.

For press releases and other company information, visit the Watson website at http://www.watson.com.

Forward-Looking Statement

Any statements contained in this press release that refer to future events or other non-historical facts are forward-looking statements that reflect Watson's current perspective of existing trends and information as of the date of this release. Except as expressly required by law, Watson disclaims any intent or obligation to update these forward-looking statements. Actual results may differ materially from Watson's current expectations depending upon a number of factors affecting Watson's business. These factors include, among others, the impact of competitive products and pricing; market acceptance of and continued demand for Watson's prod
'/>"/>

SOURCE Watson Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Biopten (Sapropterin Dihydrochloride) Approved by Japanese Ministry of Health for the Treatment of PKU
2. Shires ELAPRASE(R) (idursulfase) Approved in Japan for the Treatment of Hunter Syndrome
3. Anesiva Outlines Comprehensive Commercialization Plan for FDA Approved Product Zingo(TM)
4. Healthcare Announced That an Overwhelming Majority of its Shareholders Approved the NexGen Biofuels Transaction
5. Bystolic(TM), a Novel Beta Blocker, is Now Approved by the FDA for the Treatment of Hypertension
6. Avastin Approved in Europe for First-Line Treatment of Patients With Advanced Kidney Cancer
7. EVICEL(TM) Fibrin Sealant (Human) Approved for General Hemostasis in Surgery
8. Clexane(R)/Lovenox(R) Approved in Japan
9. Shires ELAPRASE(R) (idursulfase) Approved in Mexico for Treatment of Hunter Syndrome
10. Center for Molecular Medicine Among First to Offer New FDA-Approved Test to Aid in Treatment of Prostate Cancer
11. Lucids VivaScope(R) Reflective Confocal Microscope Approved for Sale in China
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/16/2014)... 16, 2014 “Nature has developed, very ... that we desire in optical design,” said Joseph Shaw, ... University. “As we explore surfaces and structures at the ... were presented in San Diego in August during a ... Nature ” chaired by Shaw and Rongguang Liang of ...
(Date:9/16/2014)... phones to cars and flashlights, batteries play an ... companies constantly are seeking ways to improve battery ... using a water-based solution, researchers at the University ... efficient nuclear battery that could be used for ... in automobiles and also in complicated applications such ...
(Date:9/16/2014)... MA (PRWEB) September 16, 2014 CIRTEC ... of Brian Highley as CEO of CIRTEC. , ... exciting point for the Company.” noted Brian Highley. “The ... performance while sustaining strong organic growth over the past ... growth by continuing to improve and expand the services ...
(Date:9/16/2014)...  LABSCO, the leading specialty sales agent of ... office laboratories and alternate healthcare settings is proud ... will serve as Siemens Healthcare Diagnostics, exclusive sales ... a semi-exclusive sales distributor in specified POL market ... States . LABSCO will be responsible for ...
Breaking Biology Technology:Nature’s designs inspire research into new light-based technologies 2Nature’s designs inspire research into new light-based technologies 3Nature’s designs inspire research into new light-based technologies 4Nature’s designs inspire research into new light-based technologies 5LABSCO Secures Alliance With Siemens Healthcare Diagnostics 2LABSCO Secures Alliance With Siemens Healthcare Diagnostics 3
... engine dedicated to recruiting exceptional talent to jobs at ... the most rewarding careers on the planet, but they ... StartUpHire website, www.startuphire.com , lists thousands of jobs ... investor, and more. Search agents allow users to ...
... (Pink Sheets: SYNJ), Reports that it has engaged in ... The job of the Director will be to coordinate ... Pinnacle Energy Division. The Company is currently considering ventures ... production, and microwave plasma physics. To that end, the ...
... NOVATO, Calif., March 18 BioMarin Pharmaceutical Inc. (Nasdaq: ... for clinical trial authorization (CTA) for BMN 110 or ... lysosomal storage disorder Mucopolysaccharidosis Type IVA (MPS IVA), or ... Kingdom Medicines and Healthcare Products Regulatory Agency (MHRA). BioMarin ...
Cached Biology Technology:StartUpHire Launches Comprehensive Search Engine for Jobs at Venture-Backed Companies 2StartUpHire Launches Comprehensive Search Engine for Jobs at Venture-Backed Companies 3Syndication Inc. Seeks 'DIRECTOR OF TECHNICAL ENGINEERING' for 'PINNACLE ENERGY' - Its New Alternative Energy Subsidiary 2BioMarin's Clinical Trial Application for GALNS for Morquio A Syndrome Accepted by the MHRA 2BioMarin's Clinical Trial Application for GALNS for Morquio A Syndrome Accepted by the MHRA 3BioMarin's Clinical Trial Application for GALNS for Morquio A Syndrome Accepted by the MHRA 4
(Date:9/16/2014)... such as buying clothing not made in a sweat ... their own bags when they go shopping? According to ... Research , ethical consumption is motivated by a need ... into action. , "Advocates of ethical consumerism suggest that ... the products they choose, but unfortunately only a small ...
(Date:9/16/2014)... Sept. 16, 2014  Cross Match Technologies, a ... announced today the launch of its Verifier ® ... identity of an individual using their secure credentials ... rapidly reads credential documents with embedded biometric data ... the biometric to a live scan of their ...
(Date:9/15/2014)... (September 15, 2014) The so-called central dogma ... proteinhas long provided a simplified explanation for how ... organisms. , In reality, of course, the ... first articulated nearly 60 years ago by Nobel ... structure. For one, there are multiple types of ...
Breaking Biology News(10 mins):Why are consumers willing to spend more money on ethical products? 2Cross Match Launches New Identity Management Handheld Solution 2Scientists discover RNA modifications in some unexpected places 2
... discovery by UNC scientists describes how cells infected by ... called exosomes, changing their cellular "cargo" of proteins and ... the growth of recipient cells from benign to cancer-producing. ... effects and potentially manipulate other cells throughout the body. ...
... University of California, San Diego School of Medicine and ... approved drugs to more than 1,000 proteins in Mycobacterium ... avenues to repurpose these drugs to treat TB. ... Computational Biology . "Tuberculosis is currently one of ...
... study by researchers at the Johns Hopkins Bloomberg School of ... disease among male clients of the commercial sex industry in ... drug use as the primary transmission mode of all HIV ... of publication in the journal Sexually Transmitted Infections . ...
Cached Biology News:UNC scientists identify cellular communicators for cancer virus 2TB-drugome provides new targets for anti-tuberculosis drug discovery 2Study examines risk of heterosexual HIV transmission in China 2